Company Description
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis.
It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine.
In addition, the company’s early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator.
Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform.
The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015.
Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 101 |
| CEO | Lindsay Rosenwald |
Contact Details
Address: 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 United States | |
| Phone | 781 652 4500 |
| Website | fortressbiotech.com |
Stock Details
| Ticker Symbol | FBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001429260 |
| CUSIP Number | 34960Q109 |
| ISIN Number | US34960Q3074 |
| Employer ID | 20-5157386 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lindsay Allan Rosenwald | Executive Chairman, President and Chief Executive Officer |
| David Jin | Chief Financial Officer and Head of Corporate Development |
| Dr. Xiaoqin Lu M.D. | Chief Strategy Officer |
| Michael S. Weiss Esq. | Executive Vice Chairman of Strategic Development and Director |
| Samuel Berry | General Counsel and Corporate Secretary |
| Dr. George C. Avgerinos | Senior Vice President of Biologics Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | 8-K | Current Report |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 16, 2025 | 8-K | Current Report |
| Apr 2, 2025 | EFFECT | Notice of Effectiveness |
| Apr 2, 2025 | EFFECT | Notice of Effectiveness |
| Apr 2, 2025 | EFFECT | Notice of Effectiveness |
| Apr 2, 2025 | EFFECT | Notice of Effectiveness |